Genenta Science S.p.A. announced on November 14, 2024, its letter of intent with AGC Biologics from October 31, 2024, to negotiate a manufacturing agreement for cell therapy products, reserving an exclusive suite and possible financial commitments. The proposed deal should be finalized by December 15, 2024, involving payments if not executed.